These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36354581)

  • 21. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
    Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
    PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
    Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
    Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Multi-Disulfide Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein Expressed in
    Brindha S; Kuroda Y
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
    Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
    Front Immunol; 2022; 13():871874. PubMed ID: 35898497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies.
    Maghsood F; Amiri MM; Zarnani AH; Salimi V; Kardar GA; Khoshnoodi J; Mobini M; Ahmadi Zare H; Ghaderi A; Jeddi-Tehrani M; Schmidt S; Laumond G; Moog C; Shokri F
    Front Med (Lausanne); 2022; 9():973036. PubMed ID: 36148457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
    Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
    Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq.
    Rashid PMA; Salih GF
    Mol Biol Rep; 2022 Aug; 49(8):7437-7445. PubMed ID: 35698014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
    Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
    Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    Kumar S; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations.
    Solanki K; Rajpoot S; Kumar A; J Zhang KY; Ohishi T; Hirani N; Wadhonkar K; Patidar P; Pan Q; Baig MS
    Future Virol; 2022 Jul; ():. PubMed ID: 35935449
    [No Abstract]   [Full Text] [Related]  

  • 37. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2.
    Philip AM; Ahmed WS; Biswas KH
    Comput Struct Biotechnol J; 2023; 21():1966-1977. PubMed ID: 36936816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2.
    Gong SY; Ding S; Benlarbi M; Chen Y; Vézina D; Marchitto L; Beaudoin-Bussières G; Goyette G; Bourassa C; Bo Y; Medjahed H; Levade I; Pazgier M; Côté M; Richard J; Prévost J; Finzi A
    Viruses; 2022 Sep; 14(10):. PubMed ID: 36298733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.